MKRN1: A RING-Type E3 Ubiquitin Transferase Makorin-1 as a Drug Target and Biomarker

MKRN1: A RING-Type E3 Ubiquitin Transferase Makorin-1 as a Drug Target and Biomarker

Molecular biology has revolutionized our understanding of cellular signaling and protein function. One of the essential components of the ubiquitin system is the RING-type E3 ubiquitin transferase (RING-E3), which plays a crucial role in the regulation of protein stability and dynamics. RING-E3 ubiquitin transferases are known to participate in various cellular processes, including cell signaling, DNA damage repair, and inflammation. The MKRN1 protein, a member of the RING-E3 ubiquitin transferase family, has been identified as a potential drug target and biomarker for various diseases.

MKRN1: A RING-Type E3 Ubiquitin Transferase

MKRN1, also known as Makorin-1, is a 21-kDa protein that belongs to the RING-type E3 ubiquitin transferase family. This family of enzymes plays a central role in the regulation of protein stability and dynamics by transferring a ubiquitin tag to target proteins. MKRN1 is characterized by a unique N-terminal region that contains a short amino acid sequence known as \"YXXL\" and a C-terminal region that contains a long amino acid sequence involved in the RING-E3 ubiquitin transferase activity.

MKRN1 is expressed in various cell types, including neurons, macrophages, and cancer cells. It has been shown to play a role in various cellular processes, including cell signaling, DNA damage repair, and inflammation. For example, MKRN1 has been shown to be involved in the regulation of neuronal excitability and synaptic plasticity. It has also been shown to play a role in the regulation of cell apoptosis, which is a critical event in the control of cellular aging and disease.

MKRN1 as a Drug Target

The RING-E3 ubiquitin transferase family is a promising drug target for various diseases due to their unique ability to transfer a ubiquitin tag to target proteins. MKRN1, as a RING-E3 ubiquitin transferase, has been shown to be involved in various cellular processes and can be targeted by small molecules.

One of the potential benefits of targeting MKRN1 is its potential to treat various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression. These disorders are characterized by the accumulation of misfolded proteins, including amyloid beta-peptides and tau tangles, which are thought to contribute to the neurodegeneration that occurs in these disorders. Targeting MKRN1 with small molecules that interfere with its function could potentially lead to the relief of these symptoms.

Another potential target for MKRN1 is its role in cancer. Many cancer cells have increased levels of misfolded proteins, including Aurora B mutations, which are thought to contribute to the development and progression of cancer. Targeting MKRN1 with small molecules that interfere with its function could potentially lead to the inhibition of cancer cell growth and the inhibition of Aurora B mutations.

MKRN1 as a Biomarker

MKRN1 has also been shown to be a potential biomarker for various diseases. The RING-E3 ubiquitin transferase family is known to play a role in the regulation of protein stability and dynamics, and the levels of MKRN1 in cells can be affected by various factors, including stress, chemo-therapy, and disease. Therefore, the levels of MKRN1 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Conclusion

MKRN1 is a unique protein that belongs to the RING-type E3 ubiquitin transferase family. It is expressed in various cell types and has been shown to play a role in various cellular processes, including cell signaling, DNA damage repair,

Protein Name: Makorin Ring Finger Protein 1

Functions: E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include FILIP1, p53/TP53, CDKN1A and TERT. Keeps cells alive by suppressing p53/TP53 under normal conditions, but stimulates apoptosis by repressing CDKN1A under stress conditions. Acts as a negative regulator of telomerase. Has negative and positive effects on RNA polymerase II-dependent transcription

The "MKRN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKRN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2